Home > Courses > Bivalent & Quadrivalent Human Papillomavirus Vaccines: The Current Status & Future Prospects for HIV Prevention
Bivalent & Quadrivalent Human Papillomavirus Vaccines: The Current Status & Future Prospects for HIV Prevention
Sorry, this learning module is not available for mobile devices.
COPYRIGHT: Videos of live meetings of PRN in NYC are owned and published by Physicians' Research Network, Inc. Copyright © 2009. All rights reserved.
COLLABORATION STATEMENT: The AIDS Institute is proud of the ongoing collaboration between the Clinical Education Initiative (CEI) and Physicians Research Network (PRN). Founded in 1990, PRN has a well-established reputation for spotlighting the work of the most innovative and influential leaders in the HIV treatment, prevention and research fields through its monthly meetings in New York City. Since 2010, CEI has featured recordings of PRN's monthly events through the CEI website. The combined efforts of both educational institutions have enhanced the continuing educational resources available to New York State clinicians caring for people living with, or at risk for HIV.
Original Release Date: 10/20/2009
Review Date: 10/20/2009
Jennifer S. Smith, PhD, MPH
University of North Carolina
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
- Review clinical trials data to explain the efficacy of current generation HPV prophylactic vaccines.
- Describe the association between increases in HPV infection and cervical cancer among HIV-seropositive individuals.
- Explain the current data on associations between HPV status and HIV acquisition.
Jennifer S. Smith is an Associate Professor in Research within the Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina. Dr. Smith has conducted research on HPV and associated cervical neoplasia since 1995. Her current research focuses on epidemiological studies of human papillomavirus (HPV) and cervical cancer worldwide, with a focus on prevention via HPV self-screening and prophylactic vaccines.
PRN Learning Modules